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In most risk stratification and intervention postinfarction
trials, cardiac mortality is used as the major outcome end
point either alone or in combination with nonfatal reinfarc-
tion. However, the independent risk carried by nonfatal
reinfarction for subsequent cardiac death has not been
quantified. The prognostic significance of nonfatal reinfarc-
tion was determined from the multicenter diltiazem trial
data base of 1,234 patients treated with placebo foUowed up
for 1 to 4 years after acute myocardial infarction. One
hundred sixteen patients had at least one nonfatal reinfarc-
tion, 14 (12%) of whom subsequently experienced cardiac
death. Of the remaining 1,118 patients without nonfatal
reinfarction, 110 (9.8%) experienced cardiac death. Com-
pared with event-free patients, patients with nonfatal rein-
farction were more likely (p < 0.05) to be women, to have
had an infarction before their index event and to have had
prior cardiac-related symptoms.
In most risk stratification and intervention postinfarction
trials, cardiac mortality is used as a major outcome end
point, but it is often combined with nonfatal reinfarction to
form a single composite end point, the first recurrent cardiac
event (1-9). Use of this combined end point is based on the
assumption that similar pathophysiologic mechanisms
(namely, ischemia) operate in both, and that nonfatal rein-
farction increases the subsequent risk for cardiac mortality,
mainly by increasing the degree of mechanical dysfunction.
The relation between nonfatal reinfarction and subsequent
cardiac death has not been evaluated in detail or quantified,
although an understanding of it is essential for secondary
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Cox survivorship analyses, using pertinent baseline clin-
ical variables along with nonfatal reinfarction as a time-
dependent predictor variable, revealed that nonfatal rein-
farction carried a significant and independent risk for
subsequent cardiac mortality (hazard ratio 3.0, p =0.002),
which was greater than that carried by other significant
predictor variables (New York Heart Association functional
class, pulmonary congestion on chest radiograph, blood
urea nitrogen level, predischarge Holter-recorded ventric-
ular premature complexes and radionuclide ejection frac-
tion). The cardiac mortality risk associated with nonfatal
reinfarction was further increased in patients whose index
event was their first infarction (hazard ratio 5.4, p =
0.0006). Thus, nonfatal reinfarction carries a strong, sig-
nificant and independent risk for subsequent cardiac death
in patients surviving an acute myocardial infarction.
(J Am Coil CardioI1990;15:253-8)
prevention strategies. The purpose of this study is to exam-
ine the clinical determinants of cardiac death and nonfatal
reinfarction and to determine the independent contribution
of nonfatal reinfarction to the risk of subsequent cardiac
death.
Methods
Study patients. A detailed description of the design,
population, data acquisition, data management and follow-
up of the Multicenter Diltiazem Postinfarction Trial has been
previously reported (9). The population for the present study
included only the placebo-assigned patients of the total trial
population. There were 38 participating hospitals from 23
centers, 19 in the United StateS and 4 in Canada. The
placebo group included 1,234 patients, aged 25 to 75 years,
who had a documented acute myocardial infarction between
February 1983 and June 1986. The diagnosis of acute myo-
cardial infarction required serum enzyme confirmation in
patients with symptoms or electrocardiographic changes, or
both, suggestive of an acute coronary event. None of these
patients received thrombolytic therapy. Patients had regular
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follow-up until the common termination date of June 30,
1987. Follow-up duration ranged from 12 to 52 months
(average 25 months per patient).
Data acquisition. Data acquisition was accomplished as
previously reported (9). The clinical variables collected on
each patient included demographic data, prior cardiac his-
tory, coronary care unit course, the qualifying electrocardio-
gram (ECG) and evaluation by radionuclide ejection fraction
measurement and 24 h Holter ECG monitoring, which were
performed 7.9 ± 3.9 and 6.9 ± 3.0 days (mean ± SD) after
infarction, respectively. Routine clinical variables were
missing in <0.5% of the patients, radionuclide ejection
fraction measurement was not performed in 12% and Holter
monitoring was not performed in 13% of the patients.
Definitions. Aftrst recurrent cardiac event was defined as
a nonfatal reinfarction (nonfatal event) or cardiac death (fatal
event), whichever occurred first. Patients who experienced
cardiac death after surviving hospitalization for a nonfatal
reinfarction were categorized in the nonfatal event group.
Variables. The following variables were preselected and
dichotomized as the principal, clinically meaningful covari-
ates for the analyses reported here: age (~60 years), male
gender, prior myocardial infarction (self-reported), New
York Heart Association functional classification class II to
IV I month before the index infarction, any grade of pulmo-
nary congestion on chest radiograph, index infarction type
(Q wave anterolateral, Q wave inferoposterior and non-Q
wave) according to the Manhattan code (10), blood urea
nitrogen (>35 mg/dl), radionuclide left ventricular ejection
fraction «40%), Holter-recorded ventricular premature
complexes (~IO/h) and occurrence of the first nonfatal
reinfarction during follow-up. Nonfatal reinfarction was cat-
egorized by a three member subcommittee that reviewed all
information obtained by the study coordinators regarding
patients rehospitalized with acute coronary events. The
criteria for reinfarction were the same as those used for
defining the index infarction. Patients who had survived their
reinfarction hospitalization were. categorized as having had a
nonfatal reinfarction.
Therapy and end points. Concurrent therapy was not
controlled and was left to the discretion of the patient's
personal physician. At the time of randomization to placebo
therapy 53% of the patients were taking a beta-adrenergic
blocking agent, 62% were taking nitrates and 9% were taking
an antiarrhythmic agent. The primary end point of the
analysis was cardiac death. A four member mortality sub-
committee reviewed each death case using information ob-
tained from relatives, witnesses, death certificates, attending
physicians, hospital records and autopsy reports. Each
death case was categorized as cardiac or noncardiac.
Statistical analysis. Baseline characteristics of patients
experiencing fatal and nonfatal first recurrent cardiac events
were compared using a chi-square test. Separate compari-
sons were made comparing patients with no event with
patients with a nonfatal event, and comparing patients with
a fatal event with those with a nonfatal event. A two-sided p
value of <0.05 was considered statistically significant. In
these analyses, nonfatal reinfarction served as an end point.
Cumulative reinfarction and cardiac mortality rates over
time in different subsets were described by Kaplan-Meier
curves (11), and differences between curves were assessed
by the log-rank test (12).
A stepwise logistic regression technique (13) was used to
determine the clinical variables that best predicted the
fatality of a given follow-up cardiac event. This analysis
included only patients with an event, using the fatality or
nonfatality of the event as an end point.
To determine the independent risk carried by nonfatal
reinfarctionfor subsequent cardiac death over time, we used
the Cox proportional hazards survival model (14). In these
analyses, nonfatal reinfarction served as a time dependent
predictor variable. The independent risk for subsequent
cardiac death that is carried by each predictor variable is
reported in terms of hazard ratio-the ratio of the risk of
experiencing a cardiac death per unit of time for patients
with a certain predictor variable to the risk of patients
without that predictor variable (while adjusting for all other
variables in the model).
The mortality experience of patients with nonfatal rein-
farction was compared with that of a control group. This
subset analysis included only patients without a history of a
pre-enrollment infarction. The selection procedure of the
control group was designed after that of Prentice (15). The
control group consisted of five matched control patients for
each patient with nonfatal reinfarction. Matching criteria
included event-free survival time to reinfarction, left ventric-
ular ejection fraction dichotomized at 40% and the presence
or absence of pulmonary congestion on chest radiograph.
After the matching procedure, control patients were ran-
domly selected, five at a time, without replacement. To
avoid retrospective bias, the matching technique allowed
selection of patients with "late" nonfatal reinfarction as
control patients for patients with "early" nonfatal reinfarc-
tion. Consequently, a patient who experienced a nonfatal
reinfarction 6 months after his first infarction could be
randomly selected as a control case for a patient who
experienced a nonfatal reinfarction 2 months after his first
infarction. Such a control patient was kept in the control
group until reinfarction occurred, at which time he was
censored from the control group and moved to the reinfarc-
tion group. Six independent sets of 5: 1 matched control
groups were randomly selected. Comparisons of the cardiac
mortality over time between the patients with nonfatal
reinfarction and each of the six matched control groups were
similar. A representative control group was selected for
graphic cardiac mortality comparison with the nonfatal rein-
farction group using the method of Kaplan and Meier (11).
The reported analyses utilized the Multicenter Diltiazem
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Figure 1. Cumulative first nonfatal reinfarction rate in 1,233 pa-
tients with and without prior (pre-enrollment) infarction.
Postinfarction Trial analytic data base released November 1,
1987.
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Characteristic
Age (::=060 years)
Male gender
Prior MI
NYHA class II to IV
Acute anterolateral Q wave
Acute inferoposterior Q wave
Acute non-Q wave MI
LVEF «40%)
Pulmonary congestion
VPCs (::=olO/h)
BUN (>35 mgldl)
BUN = blood urea nitrogen; LVEF = left ventricular ejection fraction;
MI = myocardial infarction; NYHA class = New York Heart Association
functional classification I month before entry; VPCs = ventricular premature
complexes recorded on Holter monitor.
Table 2. Baseline Characteristics of 1,008 Patients Without a
Cardiac Event, 116 Patients With Nonfatal Reinfarction and 110
Patients With a Fatal First Recurrent Cardiac Event
No Yes
Status (n = 1,118) (n = 116)
Survived 970 97
Cardiac death 110 14
Noncardiac death 38 5
cardiac events and with fatal cardiac events are presented in
Table 2. Patients with nonfatal reinfarction were more likely
(p < 0.05) to be women and to have had a history of an
infarction before the index event, prior cardiac symptoms
and an index infarction that was not of the inferioposterior
Q-wave type than were patients without any events. Mark-
ers of cardiac dysfunction (ejection fraction <40%, pulmo-
nary congestion, blood urea nitrogen >35 mg/dO after the
index infarction were more frequently observed (p < 0.05)
among patients who had a cardiac death than among those
who had a nonfatal reinfarction.
Clinical predictors of first cardiac event fatality. To iden-
tify clinical variables that can predict the fatal outcome of a
given recurrent cardiac event, we used a multiple logistic
regression technique (13). Only patients with an event (car-
diac death or nonfatal reinfarction) were entered into the
model. The model included 191 patients who subsequently
experienced a cardiac event during follow-up; of these 191
patients, 91 had cardiac death and 100 had nonfatal reinfarc-
tion as their first recurrent cardiac event. The same prese-
lected 11 clinical variables as in Table 2 were entered as
Table 1. Mortality Events in 1,234 Patients With and Without
Nonfatal Reinfarction
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Results
Nonfatal reinfarction: frequency of occurrence and char-
acteristics. One hundred sixteen patients (9.4%) experi-
enced a nonfatal reinfarction as their first recurrent cardiac
event during an average follow-up period of 25 months. The
clinical presentation of patients with nonfatal reinfarction
included typical central chest pressure in 96 patients
(82.8%); EeG changes during reinfarction included new Q
waves alone in 29 cases (25%) and new ST or T wave
changes in 79 (68.1%). Reinfarction was procedure-related in
only seven cases (6%). A first nonfatal reinfarction was
followed by a second nonfatal reinfarction in 13 patients
(11.2%) and by two nonfatal reinfarctions in 1 patient. The
cumulative occurrence of nonfatal reinfarction over time in
patients with and without history of an infarction before the
index event is presented in Figure 1. Nonfatal reinfarction
occurred more frequently and earlier among patients with a
history of a pre-enrollment infarction than among those
without (p = 0.0002).
Mortality. Mortality (due to cardiac and noncardiac
causes) in patients with and without nonfatal reinfarction is
summarized in Table 1. A first nonfatal reinfarction was
followed by subsequent cardiac death in 14 (12.1%) of 116
patients and by noncardiac death in five patients (4.3%).
Among the 1,118 patients who did not experience nonfatal
reinfarction, 110 (9.8%) had a cardiac death and 38 (3.4%)
died from a noncardiac cause.
Univariate associations between clinical characteristics and
recurrent cardiac events. The clinical characteristics of pa-
tients without postinfarction cardiac events, with nonfatal
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Table 3. Hazard Ratios for Postinfarction Cardiac Death by
Baseline Clinical Characteristics and the Interim Occurrence of
Nonfatal Reinfarction in All Patients (modell) and in Patients
Without Prior Infarction (model 2)
Modell Model 2
(n = 934) (n = 747)
Predictor Variable HR 95%CI HR 95%CI
Nonfatal reinfarction 3.0 (1.5,6.1) 5.4 (2.1, 14.4)
NYHA class II-IV 1.9 (1.2, 3.2) 1.6 (0.7,3.3)
Pulmonary congestion 1.3 (0.8,2.2) 2.0 (1.1, 3.9)
LVEF «40%) 2.4 (1.5, 3.9) 2.0 (1.1,3.6)
VPCs (~IO/h) 2.3 (1.4, 3.7) 2.4 (1.3,4.3)
BUN «35 mg/dl) 2.3 (1.3,4.1) 1.8 (0.8,4.2)
CI = confidence intervals; HR = hazard ratio; other abbreviations as in
Table 2.
predictor variables using first cardiac event fatality as the
outcome end point. This procedure selected three variables
as significant (p < 0.05) and independent clinical predictors
of the fatality of a given first cardiac event: reduced «40%)
left ventricular ejection fraction (chi square 15.7), increased
(>35 mg%) blood urea nitrogen level (chi square 5.7) and an
index Qwave inferior-posterior infarction (chi square 6.6).
Nonfatal reinfarction as a time-dependent predictor of
subsequent cardiac death. To determine the independent
contribution of nonfatal reinfarction to the risk of subse-
quent cardiac death while adjusting for baseline clinical
variables and the variability in time of occurrence of nonfatal
reinfarction during follow-up, a time-dependent Cox propor-
tional-hazards survival model technique was employed (14).
Nonfatal reinfarction was entered into the different models
as a time-dependent predictor variable along with the other
pertinent baseline clinical variables. The results of two
models are presented in Table 3. Nonfatal reinfarction was a
significant and independent predictor of cardiac death in
both models yet it carried more risk in patients without a
history of a pre-enrollment infarction (hazard ratio 5.4) than
in the total population (hazard ratio 3.0).
An actuarial comparison (Kaplan-Meier) of the cardiac
mortality rate in patients after a second nonfatal myocardial
infarction and in a 5: 1matched control group is presented in
Figure 2. The cardiac mortality rate was significantly greater
(p = 0.013) over time in the reinfarction group than in the
control population.
Discussion
The principal findings of this study indicate that nonfatal
reinfarction carries a significant and independent risk for
subsequent cardiac mortality in postinfarction patients. The
relative contribution of nonfatal reinfarction to the risk of
cardiac death is higher in patients with a first myocardial
infarction than in the total postinfarction population.
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Figure 2. Cumulative cardiac mortality rate in 67 patients after a
second nonfatal myocardial infarction and in a 5: I matched control
group (n = 335). See text for details.
Limitations. An important question is what influence
concurrent therapy such as beta-blocking agents or revascu-
larization procedures during follow-up might have had on the
reported findings. Medications other than calcium channel
blockers were prescribed by each patient's personal physi-
cian. Information concerning medication used in this popu-
lation was available only at specific follow-up visits during
the study period. The interpretation of the effect of medica-
tion usage such as beta blockers on reinfarction and mortal-
ity rates is too complex to be incorporated as a baseline
covariate in the Cox model. Data concerning beta-blocker
therapy discontinuation before or after the occurrence of
nonfatal reinfarction were incomplete. However, we know
that beta-blockers at randomization were utilized by approx-
imately one-half of the study population, and the percentage
of patients receiving beta-blockers was similar in the 79
patients with nonfatal reinfarction and in the 5: 1 matched
control patients. Moreover, repeated Cox analyses including
beta-blocker therapy at randomization as one of the baseline
covariates gave similar results with regard to the indepen-
dent contribution of nonfatal reinfarction to the risk of
subsequent cardiac death. Thus, we believe that the use of
beta-blockers in this population did not exert a bias on the
mortality risk contributed by nonfatal reinfarction.
Revascularization procedures were uncommon: 155 pa-
tients (12.6%) had coronary artery bypass graft surgery, and
19 patients (1.5%) had coronary angioplasty during the first
year of follow-up. Of the 116 patients with nonfatal reinfarc-
lACC Vol. 15, No.2
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tion, 25 had coronary bypass surgery during the first year of
follow-up. Of these 25 patients, only 6 had surgery before
their reinfarction whereas 19 patients (76%) had surgery
after their reinfarction. Reinfarction rate in the total follow-
up period was higher in patients who had coronary bypass
surgery during the first year (16.1%) than in those who did
not (8.4%). In view of these findings, revascularization
procedures were not included in the Cox analyses.
Cardiac mortality and nonfatal reinfarction rates. The
nonfatal reinfarction rate in our study was 7.7% in the first
year after the index infarction. This is in accordance with
previous studies (5-7,16) that reported rates of 3% to 21%
during the first year. According to the cumulative reinfarc-
tion rate curves (Fig. 1), two main slopes could be identified:
the steeper occurred 0 to 6 months after the index infarction
and the less steep >6 months after the index event. The
relative changes in the slope of the curve are similar for
patients with and without prior infarction, yet reinfarction
occurred earlier in patients with than in those without prior
infarction. These time-dependent changes in nonfatal rein-
farction rates are similar to mortality rate changes over time
observed in several postinfarction populations (1,5-9). It is
the combination of these two rates over time that describes
coronary disease activity and severity.
Univariate predictors of nonfatal reinfarction. The asso-
ciation of prior infarction and prior cardiac symptoms with
the occurrence of nonfatal reinfarction has been reported
previously (1,3,6) and is related to the fact that both varia-
bles are good clinical measures of the activity of the disease.
The association of a non-Q wave index infarction (7,17,18)
and ofa Qwave inferoposterior index infarction (19) with the
subsequent occurre~ce of nonfatal reinfarction has been
reported previously as well, but the same association for an
anterolateral Q-wave infarction has not. These univariate
associations, however, must be interpreted with caution
because they do not take into account the fact that nonfatal
reinfarction occurrence rate is indirectly influenced by
postinfarction mortality, which is mainly dependent on the
varying degrees of mechanical dysfunction that are observed
after these different index infarction types.
Independent predictors of the fatality of a given cardiac
event. Different measures of left ventricular dysfunction
were associated with a fatal cardiac event, and two of them
(reduced ejection fraction and elevated blood urea nitrogen
level) were shown to independently predict fatality in a
multivariate model. This is in agreement with the strong
association of cardiac mortality with left ventricular dys-
function (2-4,6-9,20), which has been shown to operate in
concert with ischemia during the terminal event (21) in
postinfarction patients. The finding of an independent asso-
ciation between an index infarction of the Q-wave inferopos-
terior type and the fatality ofgiven events probably relates to
the more extensive additional myocardial damage that can
occur during a subsequent event in these patients.
Nonfatal reinfarction as a predictor of cardiac mortality.
To our knowledge, this is the first study that included the
occurrence of nonfatal reinfarction as a time-dependent
predictor variable for subsequent cardiac mortality. The
time-dependent nonfatal reinfarction analysis includes all
cardiac deaths among the group under study. In principle,
the analysis can be characterized as follows. For each time
(from randomization), a separate two-way classification is
formed for all patients still at risk at that time. The "row"
classification corresponds to whether or not a patient had
suffered a nonfatal reinfarction before that time. The "col-
umn" classification corresponds to cardiac death or survival
at that time. Association in this table implies that the
occurrence of reinfarction changes the risk of cardiac death.
Such a table can be constructed at each day during follow-up
and a cardiac death hazard ratio calculated for nonfatal
reinfarction. The Cox survival analysis combines these
hazard ratios over time and has the additional capability of
adjusting these ratios for differences in baseline characteris-
tics. Thus, the reported hazard ratios for nonfatal reinfarc-
tion reflect the subsequent risk of experiencing cardiac death
for patients with a nonfatal reinfarction as compared with the
risk for patients without a nonfatal reinfarction. The inde-
pendent contribution of nonfatal reinfarction to the risk of
cardiac death was found to be highly significant and was
further increased in patients without prior infarction. This
can be accounted for by the relatively greater contribution of
reduced ejection fraction to the mortality risk in patients
with prior infarction who had significantly lower mean
ejection fraction measurements than those of patients with-
out prior infarction (40.7 ± 14.4 versus 48.1 ± 13.5, respec-
tively, p < 0.0001).
Identification of patients with subsequent reinfarction.
Our findings indicate the need to identify those patients who
are at increased risk of developing reinfarction. Most previ-
ous studies (6,7,19,22) have failed to predict nonfatal rein-
farction from baseline clinical variables. However, Dwyer et
al. (16) found that predischarge angina and prior infarction
predicted nonfatal reinfarction. Postinfarction exercise test-
ing variables (7,8,16,23-25) and coronary angiographic find-
ings (7,19,23) have not been good predictors of nonfatal
reinfarction in most previous studies. Nuclear perfusion
imaging techniques were more useful (23,24), but have not
been prospectively employed in large scale studies. In a few
previous medical intervention postinfarction trials (5,6),
medical therapy reduced both overall nonfatal reinfarction
and mortality rates over long-term follow-up. In the Beta-
Blocker Heart Attack Trial (BRAT) study (5), propranolol-
treated postinfarction patients had a lower reinfarction rate
than did placebo-assigned patients over a follow-up period of
36 months (4.4% versus 5.3%, respectively). This difference
was not statistically significant; however, the cardiac mor-
tality rate was significantly reduced by 27% in propranolol-
treated patients. In the Norwegian timolol study (6), postin-
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farction timolol therapy reduced the reinfarction rate by
28.3% at 33 months of follow-up when compared with
placebo (14.4% versus 20.1%, respectively, p = 0.0006),
whereas the cardiac mortality rate was significantly reduced
(p < 0.001) in timolol-treated patients as well. The reinfarc-
tion rate was higher in patients with than in those without
prior infarction in both treatment groups. These similar
trends of reduction in reinfarction and mortality rates in the
aforementioned intervention trials suggest a common mech-
anism for the two outcome events and might indicate that
reinfarction prevention played a role in the mortality reduc-
tion reported in these studies.
Implications. Nonfatal reinfarction carries a significant
and independent risk for subsequent cardiac death. Further
studies are needed to identify postinfarction patients who are
at increased risk for subsequent nonfatal reinfarction. There
is some evidence that reinfarction prevention can be
achieved by early interventions (medical or other) in some
subsets of postinfarction patients. The results of this study
suggest that prevention of reinfarction might contribute to a
significant mortality reduction in postinfarction patients,
particularly after a first infarction.
We thank Shirley Eberly, Eric Carleen, Mark Andrews and Michael McDer-
mott for assistance in the data analysis and Anita Oberer for secretarial
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